亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Peri-operative therapy for operable gastroesophageal adenocarcinoma: past, present and future

作者
Vassilis Aggelis,David Cunningham,Florian Lordick,Elizabeth Catherine Smyth
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:29 (6): 1377-1385 被引量:21
标识
DOI:10.1093/annonc/mdy183
摘要

Surgery represents the only chance of cure for patients with gastroesophageal adenocarcinoma; however, surgery alone does not cure most patients. Over the past decade, several multimodality adjunctive treatments have improved survival for patients with operable gastroesophageal adenocarcinoma who are undergoing surgical resection; these include peri-operative chemotherapy, neoadjuvant chemoradiotherapy, adjuvant chemotherapy and adjuvant chemoradiotherapy. More recently, the results of several large randomised trials are leading to a shift in the peri-operative treatment of gastroesophageal cancer, away from anthracycline-based and towards taxane-based chemotherapy regimens. Emerging data support an increased focus on patients who are at high risk for poor operative outcomes such as R1 resection, and on patients who are at high risk for relapse following surgery such as those with lymph node metastases (N1+). Future developments may include use of fluorodeoxyglucose-positron emission tomography to inform a switch to non-cross resistant chemotherapy pre-operatively and substitution of alternative treatments for chemotherapy in high risk post-operative node positive patients. Conversely, in molecularly selected subgroups such as microsatellite unstable gastroesophageal cancer, peri-operative or adjuvant chemotherapy may not be helpful, and treatments such as immunotherapy may be considered. In this review, the most up-to-date clinical trials and translational research in the field of operable gastroesophageal cancer are discussed; with a focus on how best to risk stratify patients with operable disease for peri-operative treatment plus surgery, and how novel therapies might be integrated into standard treatments in order to improve survival outcomes in this patient group.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
4秒前
迷路的皮皮虾完成签到,获得积分10
9秒前
Ruan发布了新的文献求助10
10秒前
兴奋的惮完成签到,获得积分10
13秒前
热爱科研的小海豹完成签到 ,获得积分10
16秒前
欢喜的铭完成签到,获得积分10
26秒前
41秒前
高高的城发布了新的文献求助10
44秒前
Maestro_S的应助被科研通管家采纳,获得10
54秒前
彭于晏的应助被高高的城采纳,获得10
59秒前
清爽的天川完成签到,获得积分10
1分钟前
1分钟前
1分钟前
呆萌雨完成签到,获得积分10
1分钟前
大胆蛟凤完成签到,获得积分10
1分钟前
迷人白桃完成签到,获得积分10
1分钟前
1分钟前
楓秋完成签到 ,获得积分10
2分钟前
mmyhn驳回了奔跑的应助
2分钟前
爱听歌鲂完成签到,获得积分10
2分钟前
2分钟前
2分钟前
英俊的铭的应助被科研通管家采纳,获得10
2分钟前
忧虑的怀曼完成签到,获得积分10
2分钟前
顺心安雁完成签到,获得积分10
2分钟前
李佳佳发布了新的文献求助10
2分钟前
mmyhn驳回了奔跑的应助
2分钟前
大熊完成签到 ,获得积分10
3分钟前
qin完成签到 ,获得积分10
3分钟前
3分钟前
光亮豌豆完成签到,获得积分10
3分钟前
无私的迎蓉完成签到,获得积分10
3分钟前
3分钟前
3分钟前
3分钟前
每天吃土发布了新的文献求助10
3分钟前
奔跑的应助被mmyhn采纳,获得10
3分钟前
汉堡包的应助被每天吃土采纳,获得10
4分钟前
4分钟前
酷炫的又蓝完成签到,获得积分10
4分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173088
求助须知:如何正确求助?哪些是违规求助? 9565519
关于积分的说明 21780437
捐赠科研通 7767172
什么是DOI,文献DOI怎么找? 3431536
关于科研通互助平台的介绍 2555678
邀请新用户注册赠送积分活动 2476675